Met Non Small Cell Cancer Registry (MOMENT)

Condition(s) studied

Study summary

The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.

The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.

Eligibility

Primary outcome measure(s)

• Best Overall Response (BOR) — Through study completion, up to approximately 4.9 years
• Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 — Up to approximately 4.9 years
• Overall Survival (OS) — Through study completion, up to approximately 4.9 years
• Number of Participants with Adverse Events (AEs) — Up to approximately 4.9 years
• Number of Participants with Adverse Reactions (ARs) — Up to approximately 4.9 years

Trial sites (79)

+ 39 more sites — see the full list on the official registry below.